Canoe Financial’s AstraZeneca AZN Stock Holding History

Canoe Financial’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-280,915	Closed	-$51.7M	–	141
2023 Q3	$51.7M	Sell	280,915 -1,066	-0.4%	-$146K	1.44%	29
2023 Q2	$40.4M	Sell	281,981 -11,953	-4%	-$1.76M	0.84%	42
2023 Q1	$40.8M	Buy	+293,934	New	+$39.5M	0.57%	61

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Canoe Financial's AZN Position: Q4 2023 in Review

Canoe Financial sold out of AstraZeneca (AZN) in Q4 2023, closing a stake of 280,915 shares — an estimated $51.7M sold.

Canoe Financial first reported a position in AZN in Q1 2023 and held it in 3 quarters. The position peaked at $51.7M in Q3 2023. 1,130 funds tracked by Wall St. Rank hold AZN as of Q4 2023.

Canoe Financial reported no remaining AstraZeneca position as of Q4 2023 after selling out during the quarter.
Canoe Financial sold 280,915 AstraZeneca shares in Q4 2023, an estimated $51.7M.
Canoe Financial first reported a position in AstraZeneca in Q1 2023 and held it in 3 quarters.
Canoe Financial's AstraZeneca position peaked at $51.7M in Q3 2023.
1,130 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2023.

Based on Canoe Financial's 13F filing for Q4 2023, filed 7 Feb 2024.